Overcoming barriers for expanding market access to follow-on biologics in lower-middle-income countries

Read full text Summarise with VIRAT
Authors: Karen MacDonald, Abidemi O. Okechukwu, Hung Phan, Nimer S. Alkhatib, Luy Xit Nguyen, Joseph P. Fuhr, Matthias Calamia, Ivo L Abraham
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Biologic therapies are highly effective for cancers, autoimmune and inflammatory conditions, diabetes, and other chronic diseases, yet remain largely out of reach in low- and lower-middle-income countries despite the rising non-communicable disease burden in these countries. Only about 1 billion of the world's 8 billion people can access biologics, concentrated in upper-middle- and high-income countries. Focusing on lower-middle-income countries (L-MICs), we assess barriers to originator and follow-on biologics (FOBs) and the opportunities to overcome them. Profiles of six geographically dispersed L-MICs serve as exemplars of the current capabilities and challenges of providing biological therapy in these countries. AREAS COVERED: Regulatory, manufacturing and supply-chain, infrastructure, financing, and clinical constraints in L-MICs were identified as barriers to accessibility to biologics and FOBs. Actionable opportunities to overcome them include regulatory harmonization and reliance, technology transfer and local production, pooled procurement, income-indexed differential pricing, prescriber education, and clinician and patient trust campaigns. The cost-efficiencies that lower-cost FOBs can generate at equivalent clinical benefit could be reinvested to expand access on a budget-neutral basis. The profiles of the six selected L-MICs demonstrated heterogeneity with regards to population size, disease burden, and current capabilities and challenges to expand access to FOBs. CONCLUSIONS: The access gap is now less about molecules than about the architecture around them. Aligning the fair-profit motive with the access imperative can make expansion a growth strategy rather than charity, with regulatory reliance and differential pricing as near-term unlocks and the coupling of cost-efficiency to expanded access as the organizing logic. Framing recommendations across micro, meso, and macro levels, we propose a shared, adaptable blueprint that lets each country copy and adapt to open new markets, close treatment gaps, and contribute meaningfully to global health equity.

Publication details

Journal / source
Journal of Medical Economics
Publisher
Informa
Volume
29
Issue
1
Pages
2650-2674
Document type
Article